La catena delle opzioni mostra i dati chiave delle opzioni azionarie di PharmaCyte Biotech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per PharmaCyte Biotech..

PharmaCyte Biotech (NASDAQ:PMCB) Azioni, Catena delle Opzioni

PharmaCyte Biotech

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares closed Monday at their highest levels ever and have now nearly doubled since the start of the year. Here&#8217;s a look at what&#8217;s been fueling the momentum in the <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46398720/palantir-stock-is-gaining-again-on-monday-whats-going-on">AI software company&#8217;s stock</a>.
AI Momentum: Palantir shares have risen more than 97% year-to-date on the back of AI-related tailwinds. The company continues to see strong demand for its Artificial Intelligence Platform, which has helped it become one of the best-performing names in the S&amp;P 500 in recent years. 
In the words of co-founder and CEO Alex Karp, Palantir is &#8220;delivering the operating system for the modern enterprise in the era of AI.&#8221; Karp said last quarter that the company was in the middle of a &#8220;tectonic shift&#8221; in the adoption of its software.
Palantir beat analyst estimates on the top and bottom lines when it reported <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">first-quarter results</a> in May. U.S. Commercial revenue increased 71% year-over-year and U.S. Government revenue climbed 45%. 
Palantir&#8217;s customer count also grew 39% year-over-year and 8% on a quarter-over-quarter basis, which included 139 deals worth over $1 million during the first quarter and 51 deals worth at least $5 million.
After the market closed on Monday, Palantir scheduled its second-quarter earnings for after the market close on Aug. 4. Analysts currently expect the company to report earnings of 14 cents per share and revenue of $939.71 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Analysts are divided on where Palantir shares are headed. Some analysts maintained Neutral or Underperform ratings following the company&#8217;s first-quarter results, with price targets as low as $90. Others see more room to run with Loop Capital increasing its price target to $155 last month and Wedbush raising its target to a Street-high $160 last week. 
Wedbush&#8217;s Dan Ives sees a "golden path" forward for Palantir and expects the company to be a "core winner" of the trillions of AI spend anticipated over the next few years.
At the end of May, Ives predicted that Palantir could reach a $1 trillion market cap valuation, or approximately $427 per share, over the next two to three years. 
&#8220;You cannot talk AI revolution without saying Palantir," Ives <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46098312/palantir-stock-hits-all-time-high-whats-going-on">said</a> at the time. 
PLTR Price Action: <a href="http://benzinga.com/quote/pltr">Palantir shares</a> hit a new all-time high of $149.57 in Monday&#8217;s session before closing the day up 4.96% at $149.15, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. Palantir stock is now up approximately 61% over the past three months. The stock has a high momentum score of 98.91, according to Benzinga&nbsp;<a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">data</a>.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46400448/dan-ives-bets-on-cybersecurity-as-biggest-subsector-in-tech-for-2025-expects-strong-q2-earnings-from-crowdstrike-zscaler-palo-alto-check-point">Dan Ives Bets On Cybersecurity As &#8216;Biggest Subsector&#8217; In Tech For 2025; Expects Strong Q2 Earnings From CrowdStrike, Zscaler, Palo Alto, Check Point</a></li>
</ul>
Photo: Sundry Photography/Shutterstock.com

News

Movers

Tech

PLTR

Palantir Stock Is On Fire, Shares Hit Another All-Time High: What's Fueling The Momentum?

New superhero movie "Superman" won the weekend's box office, coming in ahead of most estimates, which may be all the more impressive given the<a href="https://www.benzinga.com/news/entertainment/25/07/46357567/superman-an-immigrant-superhero-actor-says-warner-bros-film-is-woke-issues-box-office-warning"> call for boycotts</a> over the movie's immigrant plot line.
What Happened: The DC Comics unit of Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) has a new hit film on its hands in hopes that the company's film universe <a href="https://www.benzinga.com/general/entertainment/23/02/30678077/its-a-bird-its-a-plane-its-dc-comics-new-movies-tv-shows-announced">can rise again.</a>
"Superman" grossed $125 million domestically and $95 million during its opening weekend, good for a global haul of $220 million, as reported by <a href="https://variety.com/2025/film/box-office/superman-box-office-opening-weekend-1236459080/">Variety</a>.
The film's domestic total came in line with estimates of $120 million to $130 million ahead of the weekend and beat a $100 million to $110 million estimate from the movie studio.
The opening total of $125 million makes "Superman" the third-highest opening domestically in 2025, trailing only "Minecraft" at $162 million and "Lilo &amp; Stitch" at $146 million. The movie's opening box office also surpasses the $116.0 million from "Man of Steel" in 2013, the last standalone Superman film.
"Superman's" box office totals, coming in ahead of studio estimates and in range with most experts, could be impressive given the criticism the film and director James Gunn faced in recent weeks.
The new superhero movie was called "woke" by actor Dean Cain, who famously played Superman in the TV show "Lois &amp; Clark" from 1993 to 1997.
&#8220;How woke is Hollywood going to make this character?&#8221; Cain told&nbsp;<a href="https://www.tmz.com/2025/07/09/superman-dean-cain-immigrant-controversy/" target="_blank" rel="noreferrer noopener">TMZ</a>. &#8220;How much is Disney going to change their Snow White? Why are they going to change their characters (to) exist for the times?&#8221;
Cain&#8217;s comments, reported by <a href="https://variety.com/2025/film/news/dean-cain-superman-woke-maga-backlash-immigrant-1236451732/" target="_blank" rel="noreferrer noopener">Variety</a>, follow Gunn&#8217;s statement that Superman is an &#8220;immigrant that came from other places and populated the country&#8221; in the film, adding that the film represents &#8220;the story of America.&#8221;
&#8220;For Superman, it was ‘truth, justice, and the American way.&#8217; Well, they dropped that…They came up with ‘truth, justice, and a better tomorrow.&#8217; Changing beloved characters I don&#8217;t think is a great idea. If you want to create a new character go ahead and do that,&#8221; Cain also said.
Cain predicted the immigrant plot line was a mistake that would have financial ramifications.
"I think it's going to hurt the numbers on the movie."
Cain wasn't the only one speaking out about the film's plot line, in which Superman was portrayed as an immigrant. Allies of Donald Trump's Make America Great Again movement called for a boycott over the film's immigration-themed plot.
Fox News has been referencing the film as "SuperWoke" in recent weeks. Fox News contributor Kellyanne Conway criticized the film's plot line.
&#8220;We don&#8217;t go to the movie theater to be lectured to and to have somebody throw their ideology onto us,&#8221; Conway said.
Gunn has brushed off the criticism ahead of the film&#8217;s release.
&#8220;I think this is a movie about kindness and I think that&#8217;s something everyone can relate to,&#8221; Gunn said.
The potential boycott and the film being called woke put pressure on Gunn and Warner Bros. Discovery ahead of the release. Disney previously received criticism for being perceived as "woke" with several recent movie releases, such as "Snow White," which could potentially hurt box office results.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">Top Anticipated 2025 Movies For Big Screen Success And Stocks Investors Should Watch</a>
Why It's Important: The success of "Superman" in the face of boycotts could bode well for Warner Bros. Discovery.
The film has received positive reactions from critics and fans, which could help the film's box office in the coming weeks. This comes at a cost of $225 million for the film&#8217;s production budget and $100 million for its marketing budget.
Gunn and Peter Safran took over the task of leading DC Studios in 2022 after the Warner unit released several box office duds.
"The DC vision is clear, the momentum is real, and I couldn't be more excited for what's ahead," Warner Bros. Discovery CEO David Zaslav said after the film's success.
The future of DC Studios films includes a 10-year plan of films and spinoffs, such as "Supergirl" and "Clayface," both set for 2026 releases.
Warner Bros. and Zaslav are hoping that Gunn can replicate some of the magic he had with the "Guardians of the Galaxy" franchise for Disney, bringing DC Studios closer to the box office success that the Marvel Cinematic Universe has achieved for Disney.
WBD Price Action: Warner Bros. stock was up 2.4% to $12.01 on Monday versus a 52-week trading range of $6.64 to $12.70.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46299629/amc-declares-war-on-empty-seats-with-50-midweek-discounts-genius-or-desperation">AMC Declares War On Empty Seats With 50% Midweek Discounts—Genius Or Desperation?</a></li>
</ul>
Photo: John B Hewitt / Shutterstock.com

Entertainment

Politics

General

It's A Bird, It's A Plane, It's A MAGA Boycott Movement Taken Down: Superman Wins Box Office

CHDN

Churchill Downs To Buy 90% Of Casino Salem For $180M

Offerings

PROK

ProKidney Corp Files For Common Stock Offering Of Up To $200M; Says In The Offering, Co May Offer And Sell Shares Of Class A Common Stock

Management

Newmont Corp Karyn F. Ovelmen Resigns As CFO; Peter Wexler Appointed Interim CFO

<h3>Gainers</h3>
<ul>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares moved upwards by 45.4% to $0.8 during Monday's after-market session. The company's market cap stands at $4.9 million. </li>
<li>3 E Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASK#NASDAQ">MASK</a>) shares rose 9.58% to $1.6. The company's market cap stands at $21.6 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) stock rose 8.1% to $1.2. The company's market cap stands at $27.5 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) stock moved upwards by 7.14% to $1.8. The company's market cap stands at $6.0 million. </li>
<li>BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) stock increased by 5.24% to $4.59. The company's market cap stands at $63.1 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) stock moved upwards by 4.92% to $9.8. The company's market cap stands at $13.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TROOPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROO#NASDAQ">TROO</a>) shares decreased by 19.4% to $1.08 during Monday's after-market session. The company's market cap stands at $66.0 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares decreased by 5.76% to $5.08. The market value of their outstanding shares is at $13.9 million. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares declined by 4.04% to $5.94. The company's market cap stands at $128.2 million. </li>
<li>ACM Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) shares fell 3.91% to $27.8. The market value of their outstanding shares is at $1.8 billion. </li>
<li>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) shares declined by 3.45% to $2.8. The company's market cap stands at $285.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

ACMR

BTCM

BZAI

MASK

MOVE

SAIH

SLNH

TROO

ZENA

11 Information Technology Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) stock rose 20.9% to $2.02 during Monday's after-market session. The company's market cap stands at $4.0 million. </li>
<li>Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) stock moved upwards by 10.12% to $6.2. The company's market cap stands at $105.7 million. </li>
<li>MaxsMaking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMK#NASDAQ">MAMK</a>) stock moved upwards by 6.86% to $3.27. The market value of their outstanding shares is at $56.0 million. </li>
<li>PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) shares rose 4.07% to $3.32. The market value of their outstanding shares is at $68.5 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock increased by 3.76% to $24.78. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Brightstar Lottery (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSL#NYSE">BRSL</a>) shares moved upwards by 3.37% to $15.24. The company's market cap stands at $3.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kaival Brands Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) stock declined by 24.6% to $0.51 during Monday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares decreased by 13.42% to $0.54. The company's market cap stands at $4.2 million. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares decreased by 9.7% to $0.24. The company's market cap stands at $41.5 million. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) shares declined by 8.43% to $1.74. The company's market cap stands at $682.4 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares decreased by 7.35% to $33.56. The market value of their outstanding shares is at $959.0 million. </li>
<li>Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) stock decreased by 4.28% to $2.69. The company's market cap stands at $41.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRSL

KAVL

LOBO

MAMK

NEGG

PETS

RRGB

RYET

SBET

WKHS

XELB

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) stock rose 7.9% to $6.53 during Monday's after-market session. The company's market cap stands at $274.7 million. </li>
<li>Atlantic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLN#NASDAQ">ATLN</a>) stock increased by 7.79% to $2.35. The company's market cap stands at $133.7 million. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock increased by 7.29% to $10.29. The market value of their outstanding shares is at $378.4 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock moved upwards by 7.23% to $0.68. The company's market cap stands at $2.7 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares moved upwards by 7.01% to $0.49. The market value of their outstanding shares is at $11.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares increased by 6.69% to $2.31. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) shares fell 31.0% to $3.1 during Monday's after-market session. The company's market cap stands at $545.4 million. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares fell 20.48% to $5.4. The market value of their outstanding shares is at $981.4 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares declined by 14.07% to $0.6. The market value of their outstanding shares is at $25.2 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares fell 12.95% to $1.21. The company's market cap stands at $19.2 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock decreased by 11.86% to $0.42. The company's market cap stands at $10.6 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares declined by 8.4% to $0.4. The market value of their outstanding shares is at $16.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

ANGO

ATLN

MDXG

NIVF

ORGO

QTRX

RANI

RLYB

SXTP

TLPH

VSEE

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) stock increased by 4.8% to $2.18 during Monday's after-market session. The company's market cap stands at $30.0 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) shares moved upwards by 4.47% to $7.0. The market value of their outstanding shares is at $302.7 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) shares rose 4.3% to $0.74. The company's market cap stands at $6.3 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares moved upwards by 4.19% to $0.55. The market value of their outstanding shares is at $5.0 million. </li>
<li>FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) stock rose 3.81% to $0.7. The company's market cap stands at $109.3 million. </li>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) stock rose 3.59% to $7.77. The company's market cap stands at $25.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) shares fell 5.8% to $0.64 during Monday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock fell 4.97% to $0.28. The market value of their outstanding shares is at $67.1 million. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) stock fell 4.94% to $0.77. The company's market cap stands at $21.5 million. </li>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares fell 4.79% to $1.79. The market value of their outstanding shares is at $10.2 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock decreased by 4.63% to $2.27. The market value of their outstanding shares is at $57.5 million. </li>
<li>Clean Energy Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>) stock declined by 4.53% to $0.22. The market value of their outstanding shares is at $15.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

CETY

EHGO

ENGS

FBGL

LNZA

NOTE

SRFM

12 Industrials Stocks Moving In Monday's After-Market Session

XAGEW

Trading Halt: Halt status updated at 5:05:00 PM ET: Quotation Resumption: News and Resumption Times

MGNI

Magnite Partners WIth Paramount Australia To Unlock Programmatic Access To Paramount+'s Premium Streaming Tv Inventory In Australia For The First Time

Cavco Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) ("Cavco" or the "Company") announced today that it has entered into a definitive agreement to acquire American Homestar Corporation and its subsidiaries (collectively, "American Homestar"), a Houston-based company best known in the market as Oak Creek Homes. American Homestar operates two manufacturing facilities, nineteen retail locations, writes and sells a limited number of manufactured home loans and acts as an agent for third party insurers. With 800 employees, revenues for the twelve months ended May 31, 2025 were $194 million, net income was $16.6 million and earnings before interest, taxes, depreciation, amortization, and other income ("Adjusted EBITDA") (non-GAAP)&#x2A; was $17.8 million. During that time, American Homestar produced 1,676 homes.
Cavco will acquire American Homestar for $190 million in cash, subject to customary purchase price adjustments. The acquisition is intended to be funded entirely from the Company's cash on hand and is expected to close in the Company's third quarter of fiscal year 2026, subject to applicable regulatory approvals and the satisfaction of certain customary closing conditions.

CVCO

Cavco Industries To Acquire American Homestar For $190M Cash; American Homestar Generated $194M Revenue, $16.6M Net Income, and $17.8M Adjusted EBITDA Over Past Year

The Federal Reserve is under fire from <a href="https://www.benzinga.com/news/politics/25/07/46237506/trump-says-jerome-powell-should-resign-immediately-after-fhfa-director-alleges-fed-chair-lied-about-2-5-billion-renovation-plan">the Trump administration</a> over a controversial renovation project at its Washington headquarters, which has soared past its original $2.5 billion estimate. 
In response, Fed Chair Jerome Powell ordered a review of the project amid growing political backlash and accusations of mismanagement, secrecy, and lack of oversight, according <a href="https://www.axios.com/2025/07/14/trump-powell-fed-renovations">to</a> Axios.
What Happened: As criticism mounts, the central bank published <a href="https://www.federalreserve.gov/faqs/building-project-faqs.htm">a detailed</a> FAQ on Sunday that explained changes made to the original renovation plans and the reasons behind the project's cost increases—emphasizing the need for safety upgrades—while asserting its financial independence from taxpayer funds.
Some of the questions on the FAQ page include, "Do you have new water features?" and "Is there a new VIP dining room?". The Fed responded "No" to both questions.&nbsp;
The Fed explained in the FAQ that the renovation is necessary to address safety hazards and to bring the buildings up to modern standards. The document also states that construction had revealed more asbestos than anticipated, toxic contamination in soil, and a higher-than-expected water table, which upped the costs. 
See Also:<a href="https://www.benzinga.com/news/health-care/25/07/46355532/unitedhealth-hits-reset-new-head-of-medicaid-appointed-as-ceo-reshapes-team?utm_source=articleShare"> UnitedHealth Hits Reset: New Head Of Medicaid Appointed As CEO Reshapes Team</a>
Why It Matters: The review was initiated at the request of Fed Chair Jerome Powell following public backlash over the ballooning costs of the renovation project.
Federal Housing Finance Agency Director Bill Pulte <a href="https://www.benzinga.com/news/politics/25/07/46237506/trump-says-jerome-powell-should-resign-immediately-after-fhfa-director-alleges-fed-chair-lied-about-2-5-billion-renovation-plan">alleges</a> that Powell lied about the specifics of the renovations during his Senate Banking Committee testimony.
Kevin Hassett, director of the National Economic Council, questioned how the Fed could spend such a large sum on a building without proper congressional oversight.&nbsp;
"The idea that the Fed could print money and then spend $2.5 billion on a building without real congressional oversight, it didn't occur to the people that framed the Federal Reserve Act," Hassett said Monday on CNBC's "Squawk Box.
"We've got a real problem of oversight and excess spending," he added.&nbsp;
Additionally, former Fed Governor Kevin Warsh told<a href="https://www.foxnews.com/video/6375612621112"> Fox News</a> on Sunday that the renovation costs are "outrageous" and said the central bank "has lost its way."
The Federal Reserve clarified that taxpayers do not fund the central bank, and it is not subject to the supervision of the Office of Management and Budget. 
The central bank also stated that it has coordinated with the National Capital Planning Commission on the project and that it does not believe any of the changes require further review.
It&#8217;s worth noting that President Trump has consistently scrutinized Powell <a href="https://www.benzinga.com/news/politics/25/07/46235830/trump-wants-rate-cuts-will-big-beautiful-bill-help-answer-big-fat-no">over interest rates</a> and has called for his <a href="https://www.benzinga.com/news/25/07/46352406/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sho">resignation on social media</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;</li>
</ul>
Image: Shutterstock

Government

Federal Reserve

Trump Gets FAQ'd By Powell—No Champagne Rooms, Just Clearing Cancer Dust

7 analysts have expressed a variety of opinions on Intapp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $63.57, a high estimate of $83.00, and a low estimate of $44.00. Highlighting a 13.9% decrease, the current average has fallen from the previous average price target of $73.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1752526864_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Intapp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$44.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intapp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intapp compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Intapp's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Intapp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intapp analyst ratings.</a>
<h2>All You Need to Know About Intapp</h2>
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, investment banking, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
<h3>Breaking Down Intapp's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Intapp showcased positive performance, achieving a revenue growth rate of 16.66% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Intapp's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intapp's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.61%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Intapp's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.37%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

INTA

Demystifying Intapp: Insights From 7 Analyst Reviews

Ratings for Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.33, a high estimate of $38.00, and a low estimate of $25.00. This upward trend is evident, with the current average reflecting a 13.55% increase from the previous average price target of $26.71.
<img src="https://www.benzinga.com/files/images/story/2025/1752526856_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Ncino by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ella Smith</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$27.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ncino. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ncino compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ncino's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ncino's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NCNO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ncino analyst ratings.</a>
<h2>Discovering Ncino: A Closer Look</h2>
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes &amp; workflows and utilizes data analytics &amp; artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration &amp; implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
<h3>A Deep Dive into Ncino's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Ncino showcased positive performance, achieving a revenue growth rate of 12.53% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Ncino's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.51%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.34%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.26, Ncino adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NCNO

A Glimpse Into The Expert Outlook On Ncino Through 15 Analysts

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.6, a high estimate of $98.00, and a low estimate of $86.00. Experiencing a 5.37% decline, the current average is now lower than the previous average price target of $96.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1752526846_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of SS&amp;C Technologies Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$94.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$86.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SS&amp;C Technologies Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SS&amp;C Technologies Hldgs compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for SS&amp;C Technologies Hldgs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of SS&amp;C Technologies Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SSNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SS&amp;C Technologies Hldgs analyst ratings.</a>
<h2>Unveiling the Story Behind SS&amp;C Technologies Hldgs</h2>
SS&amp;C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&amp;C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&amp;C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&amp;C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&amp;C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&amp;C completed the acquisition of Blue Prism.
<h3>Financial Milestones: SS&amp;C Technologies Hldgs's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining SS&amp;C Technologies Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.5% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.07%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): SS&amp;C Technologies Hldgs's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.2%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): SS&amp;C Technologies Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: SS&amp;C Technologies Hldgs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.04.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SSNC

5 Analysts Assess SS&C Technologies Hldgs: What You Need To Know

9 analysts have expressed a variety of opinions on Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.5, a high estimate of $14.00, and a low estimate of $8.50. This upward trend is apparent, with the current average reflecting a 5.0% increase from the previous average price target of $10.00.
<img src="https://www.benzinga.com/files/images/story/2025/1752526839_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Ford Motor by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$15.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ford Motor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ford Motor compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ford Motor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ford Motor's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/F/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ford Motor analyst ratings.</a>
<h2>About Ford Motor</h2>
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 10% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 68% of 2024 total company revenue. Ford has about 171,000 employees, including about 56,500 UAW employees, and is based in Dearborn, Michigan.
<h3>Key Indicators: Ford Motor's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Ford Motor faced challenges, resulting in a decline of approximately -4.95% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ford Motor's net margin excels beyond industry benchmarks, reaching 1.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ford Motor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.05%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Ford Motor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.17%, the company showcases efficient use of assets and strong financial health.
Debt Management: Ford Motor's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.53, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Ford Motor: 9 Analysts Share Their Views

During the last three months, 5 analysts shared their evaluations of Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Nucor and provided 12-month price targets. The average target is $148.6, accompanied by a high estimate of $162.00 and a low estimate of $140.00. This current average has increased by 2.34% from the previous average price target of $145.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1752526831_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Nucor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Curt Woodworth</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$156.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nucor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Nucor compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Nucor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nucor's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NUE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nucor analyst ratings.</a>
<h2>About Nucor</h2>
Nucor Corp manufactures steel and steel products. The company's reportable segments are steel mills, steel products, and raw materials. A majority of its revenue is derived from the steel mills segment, which is engaged in producing sheet steel (hot-rolled, cold-rolled, and galvanized), plate steel, structural steel (wide-flange beams, beam blanks, H-piling, and sheet piling), and bar steel products. Nucor manufactures steel principally from scrap steel and scrap steel substitutes using electric arc furnaces (EAFs) along with continuous casting and automated rolling mills. The steel mills segment sells its products mainly to steel service centers, fabricators, and manufacturers located in the United States, Canada, and Mexico.
<h3>Breaking Down Nucor's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Nucor's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.77% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: Nucor's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Nucor's ROE excels beyond industry benchmarks, reaching 0.77%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.45%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Nucor's debt-to-equity ratio is below the industry average. With a ratio of 0.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Nucor: Insights From 5 Analyst Reviews

In the current session, Accenture Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is trading at $279.11, after a 0.69% drop. Over the past month, the stock fell by 10.27%, and in the past year, by 13.85%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1752526819_0.png" alt="Past Year Chart" />

<h3>Accenture P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Accenture has a lower P/E than the aggregate P/E of 59.15 of the IT Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752526819_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Accenture Inc's Price Over Earnings

Ratings for Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $29.4, a high estimate of $34.00, and a low estimate of $26.00. Highlighting a 5.16% decrease, the current average has fallen from the previous average price target of $31.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752526816_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Nurix Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nurix Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Nurix Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nurix Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NRIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nurix Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Nurix Therapeutics</h2>
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
<h3>Financial Insights: Nurix Therapeutics</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Nurix Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 264.34% as of 31 May, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nurix Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -98.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -9.36%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Nurix Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.2%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Nurix Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

PharmaCyte Biotech

PharmaCyte Biotech (PMCB) Opzioni

PharmaCyte Biotech (NASDAQ:PMCB) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO